Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. News
Aug 1, 2024 - prnewswire.com
AbbVie Completes Acquisition of Cerevel Therapeutics
Jul 1, 2024 - accesswire.com
The Schall Law Firm Is Performing A Scrutiny Into Cerevel Therapeutics Holdings Inc And Proprietors Of CERE Shares Are Welcomed To Engage
Jun 30, 2024 - accesswire.com
The Schall Law Firm Is Carrying Out An Inquiry Into Cerevel Therapeutics Holdings Inc And Possessors Of CERE Shares Are Requested To Be Part Of It
Jun 29, 2024 - accesswire.com
The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Holders Of CERE Shares Are Encouraged To Participate
Cerevel Therapeutics Holdings, Inc. Quantitative Score
About Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Cerevel Therapeutics Holdings, Inc. Earnings & Revenue
Cerevel Therapeutics Holdings, Inc. Financials
Table Compare
Compare CERE metrics with: | |||
|---|---|---|---|
Earnings & Growth | CERE | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CERE | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CERE | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CERE | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Cerevel Therapeutics Holdings, Inc. Income
Cerevel Therapeutics Holdings, Inc. Balance Sheet
Cerevel Therapeutics Holdings, Inc. Cash Flow
Cerevel Therapeutics Holdings, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Cerevel Therapeutics Holdings, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Cerevel Therapeutics Holdings, Inc. Executives
| Name | Role |
|---|---|
| Mr. Ronald C. Renaud Jr., M.B.A. | President, Chief Executive Officer & Director |
| Dr. N. Anthony Coles Jr., M.P.H. | Executive Chairman |
| Dr. Ramiro Sanchez M.D. | Chief Medical Officer |
| Dr. John J. Renger Ph.D. | Chief Scientific Officer |
| Dr. Susan Altschuller M.B.A., Ph.D. | Chief Financial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Ronald C. Renaud Jr., M.B.A. | President, Chief Executive Officer & Director | Male | 1969 | 1.03M |
| Dr. N. Anthony Coles Jr., M.P.H. | Executive Chairman | 1960 | 729.77K | |
| Dr. Ramiro Sanchez M.D. | Chief Medical Officer | 1961 | 711.57K | |
| Dr. John J. Renger Ph.D. | Chief Scientific Officer | 1969 | 689.25K | |
| Dr. Susan Altschuller M.B.A., Ph.D. | Chief Financial Officer | 1982 | 633.06K |
Cerevel Therapeutics Holdings, Inc. Insider Trades
| Date | 1 Aug |
| Name | PFIZER INC |
| Role | Former 10% Owner |
| Transaction | Disposed |
| Type | U-Tender |
| Shares | 27349211 |
| Date | 1 Aug |
| Name | BAIN CAPITAL INVESTORS LLC |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 65679781 |
| Date | 1 Aug |
| Name | Gordon Christopher R |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 3282 |
| Date | 1 Aug |
| Name | Gordon Christopher R |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 10461 |
| Date | 1 Aug |
| Name | Gordon Christopher R |
| Role | Director, 10 percent owner |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 65679781 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 1 Aug | PFIZER INC | Former 10% Owner | Disposed | U-Tender | 27349211 |
| 1 Aug | BAIN CAPITAL INVESTORS LLC | Director, 10 percent owner | Disposed | D-Return | 65679781 |
| 1 Aug | Gordon Christopher R | Director, 10 percent owner | Disposed | D-Return | 3282 |
| 1 Aug | Gordon Christopher R | Director, 10 percent owner | Disposed | D-Return | 10461 |
| 1 Aug | Gordon Christopher R | Director, 10 percent owner | Disposed | D-Return | 65679781 |